TherapeuticsMD (TXMD) EBIT Growth (1y) (2011 - 2026)
Powered by 
Analysis
TherapeuticsMD (TXMD) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 7.43% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 31.43% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -111.70% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -2.34% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -15.58% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 122.51% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | -27.06% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 269.85% |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | -17.41% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.41% |
| Mar 31, 2026 | 43.56% |
| Dec 31, 2025 | -138.04% |
| Sep 30, 2025 | 23.99% |
| Jun 30, 2025 | 75.08% |
| Mar 31, 2025 | -12.17% |
| Dec 31, 2024 | 59.53% |
| Sep 30, 2024 | 36.04% |
| Jun 30, 2024 | -12.82% |
| Mar 31, 2024 | 57.18% |
| Dec 31, 2023 | -103.33% |
| Sep 30, 2023 | 87.79% |
| Jun 30, 2023 | 83.36% |
| Mar 31, 2023 | 85.08% |
| Dec 31, 2022 | 236.87% |
| Sep 30, 2022 | 63.63% |
| Jun 30, 2022 | 57.77% |
| Mar 31, 2022 | 38.95% |
| Dec 31, 2021 | -2.27% |
| Sep 30, 2021 | -59.85% |